PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Royal DSM N.V.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DSM Acquires Food Enzymes Business and Key Technology from Verenium - Royal DSM N.V. announce that they have entered into a definitive agreement under which DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium - Verenium.com / DSM.com
DSM Acquires Food Enzymes Business and Key Technology from Verenium

 

NewswireToday - /newswire/ - Heerlen, Netherlands, 2012/03/26 - Royal DSM N.V. announce that they have entered into a definitive agreement under which DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium - Verenium.com / DSM.com. Euronext: DSM KON

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Verenium today announce that they have entered into a definitive agreement under which DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of US$ 37 million. The transaction has been completed.

The acquisition includes Verenium’s oilseed processing business and IP portfolio, licenses for certain food enzymes and access to biodiversity libraries that Verenium will create using proprietary technology. The 2012 sales of these businesses are estimated at about US$ 15 million, growing rapidly in the coming years.

The purchase by DSM of these assets fully supports DSM’s strategy for its Nutrition cluster,“continued value growth”, and strengthens and broadens DSM’s enzymes business and capabilities. With the acquisition of these assets and licenses DSM will further strengthen its industrial biotech activities (e.g. in oilseed processing) and reinforce its food enzymes innovation pipeline.

Verenium is headquartered in San Diego (California, USA). It has developed a number of high-performance enzyme products and product candidates for use in industrial processes. Verenium's enzyme products minimize pollution by reducing or replacing harsh chemicals used in industrial processes while also enhancing yields in their customers’ processes.

DSM acquired Verenium’s oilseed processing business, including the R&D portfolio and partnership agreements. As part of the agreement, a number of Verenium employees will be offered to transfer to DSM. Verenium has developed Purifine® PLC, an enzyme that offers crop-based oil producers a sustainable way to improve yields as well as overall processing economics. The annual market growth for enzymes in the global crop-based oil market is expected to be about 50% in the coming years with the market potential estimated at more than USD 350 million.

DSM also acquired exclusive world-wide licenses to alpha-amylase and xylanase enzymes within the food and beverage markets. The market size for food enzymes alone is more than USD 1.3 billion.

In addition, DSM (dsm.com) will have access to the newly developed bio-diversity collection and library being created by Verenium. By extracting microbial DNA directly from collected samples the slow and often impossible task of culturing individual microbes in a laboratory is avoided. Utilizing ultra high-throughput screening technologies, Verenium mines its collection of billions of microbial genes in search of unique enzymes.

Stephen Tanda, Member of the DSM Managing Board and responsible for the Nutrition cluster, said: “This acquisition will broaden our enzymes business and fits very well in our strategy of continued value growth for our Nutrition cluster. It will also further support our leading industrial biotechnology position.”

Hans-Christian Ambjerg, President DSM Food Specialties, said: “For DSM Food Specialties this acquisition is a great step in achieving our ambitious growth strategy as we expand our enzymes business beyond our current applications. We will be able to provide sustainable enzyme solutions to rapidly growing new segments for DSM such as oilseed processing.”

About Verenium
Verenium (verenium.com), an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Royal DSM N.V.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DSM Acquires Food Enzymes Business and Key Technology from Verenium

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Royal DSM N.V. | Verenium
Publisher Contact: Herman Betten - DSM.com 
+31(0) 45 5782017 media.relations[.]dsm.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Royal DSM N.V. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Royal DSM N.V. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)